Vera Therapeutics (VERA) Stock Forecast, Price Target & Predictions
VERA Stock Forecast
Vera Therapeutics stock forecast is as follows: an average price target of $26.00 (represents a -30.11% downside from VERA’s last price of $37.20) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
VERA Price Target
The average price target for Vera Therapeutics (VERA) is $26.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $38.00 to $6.00. This represents a potential -30.11% downside from VERA's last price of $37.20.
VERA Analyst Ratings
According to 5 Wall Street analysts, Vera Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for VERA stock is 1 'Strong Buy' (20.00%), 3 'Buy' (60.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Vera Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Mar 21, 2024 | Laura Chico | Wedbush | $34.00 | $42.87 | -20.69% | -8.60% |
| Jan 26, 2024 | Ryan Deschner | Raymond James | $37.00 | $30.18 | 22.60% | -0.54% |
| Dec 18, 2023 | Ryan Deschner | Raymond James | $29.00 | $15.84 | 83.08% | -22.04% |
| Jan 04, 2023 | - | Jefferies | $6.00 | $6.37 | -5.81% | -83.87% |
| Jan 04, 2023 | - | H.C. Wainwright | $15.00 | $18.30 | -18.03% | -59.68% |
| Nov 18, 2022 | - | J.P. Morgan | $38.00 | $17.62 | 115.66% | 2.15% |
| May 02, 2022 | - | H.C. Wainwright | $35.00 | $20.00 | 75.00% | -5.91% |
The latest Vera Therapeutics stock forecast, released on Mar 21, 2024 by Laura Chico from Wedbush, set a price target of $34.00, which represents a -20.69% decrease from the stock price at the time of the forecast ($42.87), and a -8.60% decrease from VERA last price ($37.20).
Vera Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $33.33 |
| Last Closing Price | $37.20 | $37.20 | $37.20 |
| Upside/Downside | -100.00% | -100.00% | -10.40% |
In the current month, the average price target of Vera Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Vera Therapeutics's last price of $37.20. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 10, 2024 | Raymond James | Strong Buy | Strong Buy | Hold |
| Jan 26, 2024 | Oppenheimer | - | Outperform | Initialise |
| Jan 26, 2024 | Wedbush | Neutral | Neutral | Hold |
| Jan 26, 2024 | Raymond James | - | Strong Buy | Upgrade |
| Nov 10, 2023 | Jefferies | - | Buy | Upgrade |
| Jan 04, 2023 | Guggenheim | - | Buy | Initialise |
| Jan 04, 2023 | Wedbush | - | Neutral | Downgrade |
Vera Therapeutics's last stock rating was published by Raymond James on May 10, 2024. The company gave VERA a "Strong Buy" rating, the same as its previous rate.
Vera Therapeutics Financial Forecast
Vera Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Vera Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. VERA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Vera Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict VERA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Vera Therapeutics's previous annual EBITDA (undefined) of $NaN.
Vera Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-42.94M | $-39.04M | $-38.77M | $-38.36M | $-39.51M | $-36.53M | $-30.65M |
| High Forecast | $-42.94M | $-39.04M | $-38.77M | $-38.36M | $-39.51M | $-32.83M | $-30.65M |
| Low Forecast | $-42.94M | $-39.04M | $-38.77M | $-38.36M | $-39.51M | $-42.89M | $-30.65M |
| Surprise % | - | - | - | - | - | - | - |
Vera Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VERA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Vera Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Vera Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to VERA last annual SG&A of $NaN (undefined).
Vera Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.78 | $-0.71 | $-0.71 | $-0.70 | $-0.72 | $-0.67 | $-0.56 |
| High Forecast | $-0.78 | $-0.71 | $-0.71 | $-0.70 | $-0.72 | $-0.60 | $-0.56 |
| Low Forecast | $-0.78 | $-0.71 | $-0.71 | $-0.70 | $-0.72 | $-0.78 | $-0.56 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Vera Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VERA previous annual EPS of $NaN (undefined).
Vera Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| RAPT | RAPT Therapeutics | $1.83 | $42.20 | 2206.01% | Hold |
| VTYX | Ventyx Biosciences | $2.17 | $33.86 | 1460.37% | Buy |
| XLO | Xilio Therapeutics | $0.81 | $7.00 | 764.20% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.80 | $6.00 | 233.33% | Buy |
| EWTX | Edgewise Therapeutics | $17.52 | $48.00 | 173.97% | Buy |
| MLYS | Mineralys Therapeutics | $11.23 | $30.00 | 167.14% | Buy |
| ACRV | Acrivon Therapeutics | $8.08 | $21.50 | 166.09% | Buy |
| TARS | Tarsus Pharmaceuticals | $30.59 | $61.00 | 99.41% | Buy |
| ADAG | Adagene | $2.61 | $5.00 | 91.57% | Buy |
| ETON | Eton Pharmaceuticals | $4.59 | $8.50 | 85.19% | Buy |
| CGEM | Cullinan Oncology | $17.98 | $32.00 | 77.98% | Buy |
| TVTX | Travere Therapeutics | $10.98 | $19.50 | 77.60% | Buy |
| COGT | Cogent Biosciences | $10.47 | $18.50 | 76.70% | Buy |
| ALDX | Aldeyra Therapeutics | $6.13 | $10.00 | 63.13% | Buy |
| CYTK | Cytokinetics | $54.09 | $80.92 | 49.60% | Buy |
| THRD | Third Harmonic Bio | $12.00 | $16.15 | 34.58% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| TYRA | Tyra Biosciences | $20.59 | $25.00 | 21.42% | Buy |
| CNTB | Connect Biopharma | $1.25 | $1.50 | 20.00% | Buy |
| ANAB | AnaptysBio | $35.90 | $36.33 | 1.20% | Buy |
| VERA | Vera Therapeutics | $37.20 | $26.00 | -30.11% | Buy |
VERA Forecast FAQ
Is Vera Therapeutics a good buy?
Yes, according to 5 Wall Street analysts, Vera Therapeutics (VERA) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 3 'Buy' recommendations, accounting for 80.00% of VERA's total ratings.
What is VERA's price target?
Vera Therapeutics (VERA) average price target is $26 with a range of $6 to $38, implying a -30.11% from its last price of $37.2. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Vera Therapeutics stock go up soon?
According to Wall Street analysts' prediction for VERA stock, the company can go down by -30.11% (from the last price of $37.2 to the average price target of $26), up by 2.15% based on the highest stock price target, and down by -83.87% based on the lowest stock price target.
Can Vera Therapeutics stock reach $60?
VERA's average twelve months analyst stock price target of $26 does not support the claim that Vera Therapeutics can reach $60 in the near future.
What are Vera Therapeutics's analysts' financial forecasts?
Vera Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-107M (high $-103M, low $-113M), average SG&A $0 (high $0, low $0), and average EPS is $-1.949 (high $-1.882, low $-2.066). VERA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-159M (high $-159M, low $-159M), average SG&A $0 (high $0, low $0), and average EPS is $-2.907 (high $-2.907, low $-2.907).